Walker walks the walk at IDEA Pharma

IDEA Pharma is delighted to announce the appointment of Dr. Graham Walker to its IDEAtion team. Join..

Which Pharma company is leading the charge in Productive Innovation for 2012?

IDEA Pharma has launched the second annual Productive Innovation Index (PII), ranking 21 global phar..

Prepared to Launch - EBR article

For a closer look, go to: http://www.samedanltd.com/magazine/current/12 Lifecycle decisions are ..

Get down with the lingo

For something that is supposed to be so clear, the terms used in Pharma strategy can cause confu..

Sales in the City

With IDEA Pharma’s US operations securing an ever-stronger foothold, awareness is growing as t..

IDEA Pharma expands its European headquarters

As IDEA Pharma widens its net across Europe, business is booming as the ‘IDEA house’..

Like attracts like at IDEA Pharma

As the ‘IDEA revolution’ continues to make waves within Pharma, more and more compan..

Mike Rea makes the top 100 Most Inspiring People in the Life-Sciences Industry list

IDEA Pharma’s Principal IDEAtor, Mike Rea, has been voted among the PharmaVOICE Top 100 Mo..

The 5 Enemies of Innovation

The industry has a well-recognised problem. There is a prevailing view that developing drugs is ..

Not all drug development is the same: How pharmaceutical companies rank in productive innovation

IDEA Pharma makes public its annual Productive Innovation Index (PII) With only one in four ..

IDEAtion

IDEAtion is the process of building IDEAs. IDEAtion ensures the potential or the talent of a mol..

Brand Names

This is not an industry that does what is easy instead of what is best. This is not an industry ..

Communications

It used to be that those involved in the process of communication understood which part of the p..

Efficacy

Here’s the thing about Efficacy. It doesn’t exist. It is an abstract concept, a shorthan..

Scenario Planning

Cards on the table: no two ‘scenario planning’ projects are the same, or should be t..

Brand Names

This is not an industry that does what is easy instead of what is best.

This is not an industry that would ever decide to register a big bunch of meaningless names and then dole them out to whichever brand looked likely to hit market, like orange prison overalls to new inmates…

Oh, wait… That is exactly what happens. Names that could happily sit on a washing powder, Ford car or new Dell computer adorn pharmaceutical products because it is easier. That may sound harsh, but the alternative, that the companies have been misled, must surely not be right? Those companies (and it isn’t all of them, by any means) have succumbed to the lowest common denominator thinking, the management consulting handle crank that says ‘just follow the process, and whatever comes out the other end will be fine.’ Not ‘great’ but ‘OK.’ ‘”OK” will do. “Great” might go wrong, whereas this handle here, it always produces something “OK”.’
 
“Names that could happily sit on a washing powder, Ford car or new Dell computer adorn pharmaceutical products because it is easier”
 
Companies like to talk about ‘banks’ of brand names as if they have something valuable. Names that have undergone legal checks once to show that they can’t be confused for any other when they’re pronounced, or handwritten, that don’t make claims, and that aren’t owned by some litigious IT company. (They’ll have to undergo another round of tests once they’re used in anger, of course, so no saving there…) Then, when they’re pulled off the shelf and dusted down, the same salesmen that sold them to the ‘bank’ will then get paid again to research their fit to the product in question…

Here’s the thing: no name is a genuinely blank canvas. Even the companies that peddle blank canvas processes go on to test their ‘fit to concept.’ At that point, the concept may be nothing better than ‘liberation’ but the names will be tested against it. New names may even be developed against ‘liberation’ – made of syllables that derive from Assyrian deities and Norse weaponry at significant cost (and resold to consumer companies if pharma doesn’t pick them)… They will then be shown on a 7- point scale, from ‘poor fit to concept’ all the way through to ‘excellent fit to concept’. Wait… ‘Poor fit to concept’? Considering that the ‘zero’ line means ‘no fit to concept’, ‘poor fit to concept’ doesn’t just mean ‘poor fit’… It means it is actively describing something entirely different…

In all the testing we’ve seen, it is a rare name that gets beyond a 1, which is the equivalent of a shoulder shrug… Unless, of course, some directed names are included. Names like Trizivir, Lipitor or Epogen don’t have to work too hard to communicate their concept, and they’re a lot less likely to end up on the back of a car.

Let’s move on.

Consider that ‘liberation’ concept. (Ad agencies love ‘liberation’.) Let’s just think for a moment. Might there be another industry that would want to have that association for its products? Cars? Well, yes… Financial planning? Erm, yes… Underarm deodorant… Wait… Almost every industry would want a name that suggests ‘liberation’. So, when your legal department go trawling for words that mean ‘liberation’, they are up against more than a few others, and it’s likely they weren’t there first… (See WAIMO: Emotions…)

There is an assumption: give me a blank canvas and I can invest it with any associations. True. Not cheaply, of course. In fact, the blanker the canvas, the more I am going to have to spend to invest it with those associations. Give me Elidel or Brilinta and all the money I spend in the first couple of years will go on getting someone to remember the name, well before I get to mentioning they’re eczema or anti-platelet treatments. Time to market? Clearly doesn’t matter when we’re happy to take another couple of years before anyone knows they’re there and what they do…
 
“Time to market? Clearly doesn’t matter when we’re happy to take another couple of years before anyone knows they’re there and what they do…”
 
In 2007, of the top 20 brands in the US, only 4 had ‘blank canvas’ names. One company (the fastest growing of all), had precisely no blank canvas names. (That same company has a great ad in Basel airport that says something to the effect “Several billion Swiss Francs, thousands of people, hundreds of molecules, lots of trials, one medicine.’ Maybe that tends to focus the mind on making sure that ‘one medicine’ isn’t hampered by a washing powder name at launch…) Two companies have almost nothing but blank canvas names for launches in the past 10 years. Guess how well those launches have gone…

The logical conclusion is this: (to some companies) the brand name really doesn’t matter. The product will sell whatever name we give it. If there was any belief that it does matter, why saddle it with a ‘Boy Named Sue’ story from the off – a need to prove itself despite its name?

We appreciate your feedback!
Write a comment